Who is sponsoring NCT03594110?

NCT03594110 is sponsored by Boehringer Ingelheim.

What condition does NCT03594110 study?

NCT03594110 studies Chronic Kidney Disease.

What drugs are being tested in NCT03594110?

Interventions: Empagliflozin, Matching placebo.

What is the status of NCT03594110?

NCT03594110 is currently COMPLETED.

Last reviewed 2025-07-20 · How we verify

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

NCT03594110 PHASE3 COMPLETED Results posted

The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease. After completion of the interventional part of the study (primary study completion) a subset of participants will be followed up in a post-trial observational (non-interventional) manner for cardio-renal outcomes (estimated study completion date).

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE3
Status	COMPLETED
Enrolment	6609
Start date	Thu Jan 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Chronic Kidney Disease

Interventions

Empagliflozin
Matching placebo

Countries

Italy, Japan, Malaysia, United Kingdom, Germany, Canada, China, United States